Skip to main content
Premium Trial:

Request an Annual Quote

Minute Molecular Diagnostics COVID-19 Test Nabs FDA EUA

NEW YORK – Minute Molecular Diagnostics announced on Wednesday that it has received Emergency Use Authorization from the US Food and Drug Administration for its DASH SARS-CoV-2/S molecular test.

The RT-PCR test returns results in approximately 15 minutes from an anterior nasal swab and runs on the firm's DASH Analyzer, which consolidates the sample extraction, amplification, and thermocycling processes. The point-of-care platform is portable and can be operated by untrained users, the company said in a statement.

The Evanston, Illinois-based company is beginning production of the test and seeking both government and private partnerships to "accelerate the delivery" of the test and its analyzer, it added.

Development of the test, which is authorized for use in CLIA-certified labs and CLIA-waived settings, was partially funded by the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) initiative and NIH's National Institute of Biomedical Imaging and Bioengineering. The firm received $21.3 million from RADx in April 2021 to develop the test and analyzer.

Minute Molecular was founded in 2017 as part of Northwestern University's Center for Innovation in Global Health Technology. The DASH platform could also be adapted to other infectious viral and bacterial agents and sample types, the firm said.

The Scan

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.